|
Studies
|
Number of isolates
| |
Antimicrobials resistance rate reported by 12 studies (%)
| | | | | |
|---|
|
P
|
AMP
|
AML
|
E
|
STR
|
T
|
NA
|
CF
|
GM
|
CIP
|
CL
|
A/C
|
DC
|
NOR
|
CRO
|
T/S
|
CD
|
K
|
|---|
|
Lengerh et al. [13]
|
44
|
–
|
68.2
|
–
|
27.7
|
–
|
56.8
|
9.1
|
88.9
|
18.2
|
16
|
11.4
|
36.4
|
15.9
|
11.6
|
27.7
|
54.5
|
40.9
|
–
|
|
Beyene et al. [21]
|
50
|
–
|
50
|
–
|
10
|
–
|
14
|
–
|
–
|
0
|
–
|
0
|
–
|
–
|
–
|
–
|
60
|
–
|
0
|
|
Dadi et al. [10]
|
50
|
–
|
10
|
6
|
2
|
20
|
10
|
–
|
–
|
14
|
–
|
4
|
–
|
–
|
–
|
–
|
–
|
–
|
12
|
|
Kebede et al. [27]
|
13
|
–
|
–
|
–
|
23.1
|
–
|
23.1
|
7.7
|
–
|
0
|
7.7
|
53.8
|
–
|
–
|
0
|
0
|
61.5
|
–
|
–
|
|
Getamesay et al. [28]
|
20
|
–
|
30
|
80
|
55
|
–
|
15
|
20
|
70
|
70
|
10
|
0
|
–
|
–
|
–
|
0
|
20
|
–
|
–
|
|
Chanyalew et al. [25]
|
48
|
–
|
33.3
|
–
|
–
|
4.2
|
20.8
|
2.1
|
100
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Tafa et al. [24]
|
38
|
–
|
76
|
–
|
18.4
|
–
|
39.5
|
10.5
|
100
|
13.2
|
15.8
|
31.6
|
–
|
23.7
|
10.5
|
–
|
68.4
|
26.3
|
–
|
|
Ewnetu et al. [11]
|
15
|
–
|
18.8
|
–
|
18.8
|
25
|
22.2
|
12.5
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
160
|
–
|
34.1
|
–
|
14.9
|
20.5
|
30.1
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Kassa et al. [22]
|
192
|
–
|
19.8
|
–
|
2.6
|
6.3
|
2.6
|
6.3
|
96.9
|
0.5
|
–
|
–
|
–
|
–
|
2.2
|
–
|
38.5
|
2.1
|
–
|
|
Abamecha et al. [29]
|
208
|
–
|
38.9
|
–
|
50.5
|
–
|
69.2
|
3.8
|
100
|
–
|
71.2
|
51.4
|
–
|
–
|
54.3
|
–
|
–
|
45.7
|
–
|
|
Nigatu et al. [26]
|
84
|
100
|
8.3
|
–
|
60
|
13.1
|
35.7
|
0
|
40.5
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
- AMP Ampicillin, AML Amoxicillin, E Erythromycin, STR Streptomycin, T Tetracycline, NA Nalidixic acid, P Penicillin, CF Cephalothin, GM Gentamicin, CIP Ciprofloxacin, CL Chloramphenicol, A/CAmoxicillin with clavulanic acid, DC Doxycycline, NOR Norfloxacin, CRO Ceftriaxone, T/S Trimethoprim-sulfamethoxazole, CD Clindamycin, K Kanamycin
